You just read:

Tyvyt (Sintilimab Injection) Combined with ALIMTA (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC

News provided by

Innovent Biologics, Inc.

Jan 12, 2020, 23:23 ET